Dr. David Hay is the Chair of Tissue Engineering at the University of Edinburgh, where his group is defining novel ways to produce liver tissue from PSCs. They use in vitro derived tissue to better model human liver physiology and to develop supportive cell based therapies for disease. Dr. Hay also founded Stimuliver, a company that is developing a disruptive liver implant to treat critically failing liver function in humans. He talks about hepatocyte differentiation, liver disease modeling, and automating the production of cell therapies.
Featured Products and Resources:
- The StemCellfie contest is back! Enter your best cell image by April 28th for a chance to win a StemCellfie prize package.
- Reliably generate, expand, and differentiate physiologically relevant human liver organoids with HepatiCult™.
The Stem Cell Science Round Up
Reprogramming Human Somatic Cells to PSCs with Small Molecules – Researchers chemically reprogrammed human somatic cells to pluripotent stem cells that exhibit key features of embryonic stem cells.
Somatic Mutations in Mammals – Scientists performed whole-genome sequencing of intestinal crypts across 16 species of mammals, and found that somatic mutation rates are evolutionarily constrained.
A Comprehensive Map of HSC Development – A new map unveils specific milestones in the HSC maturation process and provides scientists with a blueprint for producing fully functional HSCs in the lab.
Generating Functional Rat Gametes from PSCs – Researchers produced fetal stage rat germ cells that can produce viable offspring.
Photo Reference: Courtesy of Dr. David Hay